150 related articles for article (PubMed ID: 34995900)
21. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
22. Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study.
Truelsen CG; Serup-Hansen E; Storm KS; Havelund BM; Kronborg CS; Spindler KG
Cancer Med; 2021 May; 10(10):3224-3230. PubMed ID: 33960701
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
[TBL] [Abstract][Full Text] [Related]
24. Systemic Therapies for Advanced Squamous Cell Anal Cancer.
Sclafani F; Rao S
Curr Oncol Rep; 2018 May; 20(7):53. PubMed ID: 29728940
[TBL] [Abstract][Full Text] [Related]
25. DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
Kim S; Vendrely V; Saint A; André T; Vaflard P; Samalin E; Pernot S; Bouché O; Zubir M; Desrame J; de la Fouchardière C; Smith D; Ghiringhelli F; Vienot A; Jacquin M; Klajer E; Nguyen T; François É; Taieb J; Le Malicot K; Vernerey D; Meurisse A; Borg C
Exp Hematol Oncol; 2023 Jul; 12(1):63. PubMed ID: 37480095
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I
Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
Yamagata Y; Saito K; Hirano K; Oya M
World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
[TBL] [Abstract][Full Text] [Related]
29. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Abgral R; Le Roux PY; Keromnes N; Rousset J; Valette G; Gouders D; Leleu C; Mollon D; Nowak E; Querellou S; Salaün PY
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1839-47. PubMed ID: 22895863
[TBL] [Abstract][Full Text] [Related]
30. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor inhibition in metastatic anal cancer.
Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
[TBL] [Abstract][Full Text] [Related]
34. Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma: A prospective study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
South Asian J Cancer; 2018; 7(1):11-15. PubMed ID: 29600225
[TBL] [Abstract][Full Text] [Related]
35. Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.
Kim S; Boustani J; Vernerey D; Vendrely V; Evesque L; Francois E; Quero L; Ghiringhelli F; de la Fouchardière C; Dahan L; Bouché O; Chibaudel B; Hajbi FE; Vernet C; Rebucci-Peixoto M; Feuersinger A; Maritaz C; Borg C
Front Oncol; 2022; 12():918499. PubMed ID: 36119522
[TBL] [Abstract][Full Text] [Related]
36. The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies.
Jácome AA; Morris VK; Eng C
Curr Treat Options Oncol; 2022 Aug; 23(8):1073-1085. PubMed ID: 35666353
[TBL] [Abstract][Full Text] [Related]
37. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in advanced anal cancer: Is the beginning of a new era?
Ciardiello D; Guerrera LP; Maiorano BA; Parente P; Latiano TP; Di Maio M; Ciardiello F; Troiani T; Martinelli E; Maiello E
Cancer Treat Rev; 2022 Apr; 105():102373. PubMed ID: 35279535
[TBL] [Abstract][Full Text] [Related]
39. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
[TBL] [Abstract][Full Text] [Related]
40. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR;
Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]